Literature DB >> 26016455

Oral oxymatrine preparation for chronic hepatitis B: A systematic review of randomized controlled trials.

Wei-jiang Song1,2, Jing Luo1,3, Tong Wu1, Shu-kun Yao4.   

Abstract

OBJECTIVE: To evaluate the efficacy and safety of oral oxymatrine preparation for the treatment of chronic hepatitis B (CHB).
METHODS: Randomized controlled trials (RCTs) on oral oxymatrine preparation in treating patients with CHB were retrieved until October 2013 by searching PubMed, the Cochrane Library, Embase and four Chinese databases, irrespective of language and publication status. Data extraction and data analyses were conducted according to the Cochrane standards. The risk of bias for each included trials and the quality of evidence on pre-specified outcomes were assessed. The RevMan software was used for statistical analyses.
RESULTS: Totally 52 RCTs enrolling 5,227 participants were included, of which 51 RCTs were included in meta-analyses. Oral oxymatrine preparation including oxymatrine capsule and oxymatrine tablet were associated with statistically significant effect on the clearance of hepatitis B virus (HBV) DNA, HBV surface antigen and HBV e antigen, and were beneficial to the normalization of serum alanine aminotransferase and aspartate aminotransferase. Nevertheless, the overall methodological quality and the quality of evidence in the included trials were poor. In addition, safety of oral oxymatrine preparation was not confirmed.
CONCLUSIONS: Oral oxymatrine preparation showed some potential benefits for patients with CHB. However, the overall quality of evidence was limited and the safety of oral oxymatrine preparation for CHB patients was still unproven. More high quality evidence from rigorously designed RCTs is warranted to support the clinical use of oral oxymatrine preparation for patients with CHB.

Entities:  

Keywords:  Chinese herb; alkaloid; chronic; hepatitis B; oxymatrine; systematic review

Mesh:

Substances:

Year:  2015        PMID: 26016455     DOI: 10.1007/s11655-015-2143-0

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   2.626


  14 in total

1.  Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance.

Authors:  Yu-Ping Wang; Wei Zhao; Rong Xue; Zhen-Xian Zhou; Fei Liu; Yan-Xing Han; Gang Ren; Zong-Gen Peng; Shan Cen; Hong-Shan Chen; Yu-Huan Li; Jian-Dong Jiang
Journal:  Antiviral Res       Date:  2011-01-28       Impact factor: 5.970

2.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  Ann Intern Med       Date:  2010-03-24       Impact factor: 25.391

Review 3.  Experimental studies of oxymatrine and its mechanisms of action in hepatitis B and C viral infections.

Authors:  Xie Ning Wu; Guo Jin Wang
Journal:  Chin J Dig Dis       Date:  2004

4.  Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement.

Authors:  Joel J Gagnier; Heather Boon; Paula Rochon; David Moher; Joanne Barnes; Claire Bombardier
Journal:  Ann Intern Med       Date:  2006-03-07       Impact factor: 25.391

5.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

6.  Inhibition of hepatitis B virus by oxymatrine in vivo.

Authors:  X S Chen; G J Wang; X Cai; H Y Yu; Y P Hu
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

7.  [Oxymatrine in the treatment of chronic hepatitis B for one year: a multicenter random double-blind placebo-controlled trial].

Authors:  Lun-gen Lu; Min-de Zeng; Yi-min Mao; Mo-bin Wan; Cheng-zhong Li; Cheng-wei Chen; Qing-chun Fu; Ji-yao Wang; Wei-min She; Xiong Cai; Jun Ye; Xia-qui Zhou; Hiu Wang; Shan-ming Wu; Mei-fang Tang; Jin-shui Zhu; Wei-xiong Chen
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2004-10

8.  Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; Mo-Bin Wan; Cheng-Zhong Li; Cheng-Wei Chen; Qing-Chun Fu; Ji-Yao Wang; Wei-Min She; Xiong Cai; Jun Ye; Xia-Qiu Zhou; Hui Wang; Shan-Ming Wu; Mei-Fang Tang; Jin-Shui Zhu; Wei-Xiong Chen; Hui-Quan Zhang
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 9.  Oral oxymatrine preparation for chronic hepatitis B: A systematic review of randomized controlled trials.

Authors:  Wei-jiang Song; Jing Luo; Tong Wu; Shu-kun Yao
Journal:  Chin J Integr Med       Date:  2015-05-26       Impact factor: 2.626

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21
View more
  5 in total

1.  Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B.

Authors:  Ning Liang; De Zhao Kong; Si Si Ma; Chun Li Lu; Ming Yang; Lu Da Feng; Chen Shen; Ruo Han Diao; Ling Jun Cui; Xing Yu Lu; Dimitrinka Nikolova; Janus C Jakobsen; Christian Gluud; Jian Ping Liu
Journal:  Cochrane Database Syst Rev       Date:  2019-04-03

2.  Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling.

Authors:  Size Li; Yiqun Yu; Xiaolan Bian; Li Yao; Min Li; Yan-Ru Lou; Jing Yuan; Hai-Shu Lin; Lucy Liu; Bing Han; Xiaoqiang Xiang
Journal:  Arch Toxicol       Date:  2021-03-13       Impact factor: 5.153

Review 3.  Oral oxymatrine preparation for chronic hepatitis B: A systematic review of randomized controlled trials.

Authors:  Wei-jiang Song; Jing Luo; Tong Wu; Shu-kun Yao
Journal:  Chin J Integr Med       Date:  2015-05-26       Impact factor: 2.626

4.  Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B.

Authors:  Ning Liang; De Zhao Kong; Chun Li Lu; Si Si Ma; Yu Qi Li; Dimitrinka Nikolova; Janus C Jakobsen; Christian Gluud; Jian Ping Liu
Journal:  Cochrane Database Syst Rev       Date:  2019-06-24

5.  Oxymatrine reverses epithelial-mesenchymal transition in breast cancer cells by depressing αβ3 integrin/FAK/PI3K/Akt signaling activation.

Authors:  Yan Chen; Lin Chen; Jing-Yu Zhang; Zong-Yue Chen; Ting-Ting Liu; Yan-Yan Zhang; Ling-Yun Fu; Shuang-Qin Fan; Min-Qin Zhang; Shi-Quan Gan; Nen-Ling Zhang; Xiang-Chun Shen
Journal:  Onco Targets Ther       Date:  2019-08-08       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.